Drug Overview
The ND0612 (Mitsubishi Tanabe) product line comprises two subcutaneous, continuously delivered carbidopa/levodopa liquid formulations: the lower-dose ND0612L, and the higher-dose ND0612H. ND0612L is being investigated for the treatment of moderate Parkinson’s disease, and is intended to be administered through a belt pump or patch pump. ND0612H, under development for advanced Parkinson’s disease, is delivered via a belt pump. ND0612’s continuous administration allows for steady levodopa levels over 24 hours, avoiding the fluctuations in concentration that result in peak-dose dyskinesia, and in “off” periods.
NeuroDerm had previously guided that it anticipates filing ND0612 for regulatory approval in the US via the 505(b)(2) pathway during H2 2018, and will also file for approval in the EU. The company has since been acquired by Mitsubishi Tanabe, which l.ND0612 as a Phase II development project in its pipeline, suggesting that further pivotal clinical trials are likely.
The ND0612 (Mitsubishi Tanabe) product line comprises two subcutaneous, continuously delivered carbidopa/levodopa liquid formulations: the lower-dose ND0612L, and the higher-dose ND0612H. ND0612L is being investigated for the treatment of moderate Parkinson’s disease, and is intended to be administered through a belt pump or patch pump. ND0612H, under development for advanced Parkinson’s disease, is delivered via a belt pump. ND0612’s continuous administration allows for steady levodopa levels over 24 hours, avoiding the fluctuations in concentration that result in peak-dose dyskinesia, and in “off” periods.
NeuroDerm had previously guided that it anticipates filing ND0612 for regulatory approval in the US via the 505(b)(2) pathway during H2 2018, and will also file for approval in the EU. The company has since been acquired by Mitsubishi Tanabe, which l.ND0612 as a Phase II development project in its pipeline, suggesting that further pivotal clinical trials are likely.
Table of Contents
OVERVIEWDrug Overview
Product Profiles
ND0612 : Parkinson's disease
LIST OF FIGURES
Figure 1: ND0612 for Parkinson’s disease – SWOT analysis
Figure 2: The authors drug assessment summary of ND0612 for Parkinson’s disease
Figure 3: The authors drug assessment summary of ND0612 for Parkinson’s disease
Figure 4: ND0612 sales for Parkinson’s disease across the US and five major EU markets, by country, 2016–25
LIST OF TABLES
Table 1: ND0612 drug profile
Table 2: ND0612 late-phase trials in Parkinson’s disease
Table 3: ND0612 sales for Parkinson’s disease across the US and five major EU markets, by country ($m), 2016–25
